aap Implantate announced that it successfully completed its transformation to a pure trauma player in 2016. The company reported challenging FY16 results that were below management’s original expectations, but broadly in line with the revised guidance, with sales from its continuing operations down 15% y-o-y to €10.5m. However, this was not wholly unexpected as the company has undergone a strategic transition to being a pure trauma-focused company. Increasing market penetration in Europe and the US will be key to a successful return to growth.

Continue reading

This version is programmatically created by Research Central and qualified in its entirety to the original PDF.

Powered by Research Central